Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.

The Journal of international medical research - 1 Feb 2016

Zhou Hongxuan, Dai Yun, Zhu Liqun, Wang Chun, Fei Xiaodong, Pan Qin, Chen Juxiang, Shi Xianqing, Yang Yanfeng, Tao Xiaoxing, Shi Pinghuai

Abstract excerpt

OBJECTIVE: To evaluate treatment response, survival, and the associations between KRAS mutation status and tumour expression levels of BRCA1, TYMS and SRC retrospectively in a cohort of patients with non-small cell lung cancer (NSCLC), treated exclusively with conjunctive platinum-based doublet chemotherapy. METHODS: KRAS mutation status was determined via amplification refractory mutation and multiple...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Demography

Share to Gene Expression Regulation, Neoplastic

Share to Lung Neoplasms

Share to Platinum

Share to Proto-Oncogene Proteins p21(ras)

Share to Thymidylate Synthase

Source

Open in PubMed Open full text

Identifiers

PMID: 26740498
DOI: 10.1177/0300060515607383
PMCID: PMC5536563

Genes

KRAS
BRCA1
TYMS
SRC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.PMID 26740498Read ↗

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.Semantic proximity Read ↗

Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)Semantic proximity Read ↗

Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases.Semantic proximity Read ↗

Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.Semantic proximity Read ↗

Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.Semantic proximity Read ↗

The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.Semantic proximity Read ↗

Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.